LifeMD (LFMD) Q1 2026 earnings review
Record Subscribers, But Massive Customer Acquisition Spend Sinks Earnings
LifeMD's first quarter as a pure-play telehealth business delivered a record 42,000 net subscriber additions, but at a severe cost. The company swung from steady profitability to a $4.5 million Adjusted EBITDA loss due to a 34% YoY surge in selling and marketing expenses. While management frames this as a strategic, front-loaded investment to capture GLP-1 and Women's Health market share, guidance raises a major red flag: despite exiting Q1 with record subscribers, Q2 revenue guidance implies a sequential contraction. The long-term thesis depends heavily on a massive second-half ramp in 2026.
🐂 Bull Case
The platform added 42,000 net telehealth subscribers (exiting at 365,000), representing a 26% YoY increase. Women's Health signups skyrocketed 657% QoQ, proving the viability of LifeMD's expansion into new verticals.
Gross margin expanded significantly by 420 basis points YoY to 88%, driven by favorable revenue mix and reduced fulfillment costs. Management claims a 70% reduction in customer acquisition costs for Women's Health.
🐻 Bear Case
If Q1 generated record recurring subscription additions, Q2 revenue should naturally scale. Instead, Q2 revenue guidance ($47M-$50M) implies a sequential decline from Q1's $50.2M, questioning patient retention rates and the true ROI of Q1's massive marketing spend.
Adjusted EBITDA swung wildly from a positive $4.8M in 25Q4 to a negative $4.5M in 26Q1. Achieving full-year guidance of $12M-$17M will require immense margin engineering in the second half of the year.
⚖️ Verdict: 🔴
Bearish. Despite excellent gross margins and impressive top-of-funnel acquisition, burning $4.5M in EBITDA to generate a quarter that immediately guides for sequential revenue contraction is highly concerning.
Key Themes
The Disconnect Between Subscriber Adds and Revenue Trajectory
Management touted Q1 as having 'the largest quarterly net addition in our history' (42,000 adds, up 26% YoY). However, Q1 revenue of $50.2M was actually down 1% YoY. More concerningly, Q2 guidance calls for $47M to $50M in revenue. This indicates Decelerating/Reversing sequential momentum. A subscription model with record net adds should theoretically compound sequentially; the guided contraction suggests acute retention issues, heavy discounting on initial sign-ups, or massive churn in legacy segments like men's health.
Women's Health Surges into Relevance
The deliberate pivot to diversify beyond men's health and core GLP-1 is working top-of-funnel. Women's Health patient signups achieved 657% quarter-over-quarter growth. Furthermore, the company reported an approximate 70% reduction in customer acquisition costs in this segment, proving they can achieve scalable unit economics outside of their historical core demographics.
Gross Margin Profile Accelerating
Gross margin expanded to an exceptional 88% (up 420 bps YoY). Management attributed this to a favorable product mix and lower fulfillment costs. The divestiture of the lower-margin WorkSimpli business and scale efficiencies in the proprietary digital care platform have created a highly leveraged gross profit engine—if the company can rein in its marketing bloat.
Insurance Benefit Infrastructure Scaling
The company's transition from pure cash-pay to insurance-supported care is advancing. Management confirmed they are on track to expand coverage to approximately 230 million lives this month. This B2B infrastructure is critical for long-term retention, particularly as GLP-1 medications face price compression and patients demand insurance-covered branded therapies over cash-pay compounded alternatives.
Heavy Reliance on 'Front-Loaded' Spend
Operating expenses soared, with Selling and Marketing up 34% YoY to $29.9M (consuming nearly 60% of total revenue). Management labeled this as 'opportunistic' and 'front-loaded' to drive future growth. However, this strategy carries severe execution risk. If the acquired GLP-1 and Women's Health patients churn before recovering their CAC (especially given the Q2 sequential revenue drop), this marketing spend is effectively burned capital.
Other KPIs
Stable. The company exited the quarter with $34.5 million in cash, entirely debt-free, and holds a $30 million undrawn revolving credit facility. This clean balance sheet is a vital strategic asset, ensuring they have the runway to absorb current operating losses while funding their massive patient acquisition initiatives without immediately returning to equity markets.
Growth in this segment is decelerating on an absolute basis compared to late 2024 and early 2025 hype. While sign-ups grew 120% sequentially vs Q4 2025, the total base of 'just under 100,000' shows that managing churn against low-cost compounding competitors remains an ongoing battle.
Guidance
Decelerating sequentially. The midpoint of $48.5M implies a 3.3% sequential decline from Q1's $50.2M. This blatantly contradicts the narrative of accelerating recurring revenue from Q1's record subscriber additions.
Accelerating sequentially from Q1's deep loss, but still dangerously close to break-even or negative. This suggests marketing spend will remain elevated.
To hit the $225M midpoint after a projected ~$99M H1 (Q1 actual + Q2 midpoint), LifeMD must generate ~$126M in H2. This requires massive Reversing/Accelerating growth in the back half of the year, heavily dependent on the new Women's Health and GLP-1 initiatives maturing perfectly.
With an expected ~$5M loss in H1, the company is guiding for ~$19.5M in Adjusted EBITDA in H2. Management notes this requires 'substantial second-half accretion' and an annualized run-rate exceeding $25M by Q4. The execution risk here is immense.
Key Questions
The Revenue vs. Subscriber Disconnect
You added a record 42,000 net subscribers in Q1, bringing the total to over 365,000. Given that the majority of revenue is recurring subscriptions, why does the Q2 revenue guidance midpoint ($48.5M) imply a sequential contraction from Q1 ($50.2M)?
H2 Hockey Stick Guidance
Hitting the midpoint of your FY26 Adjusted EBITDA guidance requires roughly $20 million in EBITDA generation during the second half of the year. What specific marketing efficiency levers will you pull to achieve this, and what gives you confidence you can pull back on marketing without stalling growth?
Churn in Legacy Core
With Women's Health and Weight Management driving the bulk of top-of-funnel signups, what are the underlying retention and revenue trends in the legacy RexMD men's health business?